CN107412393B - 一种黄皮叶多酚提取物的制备方法及其应用 - Google Patents
一种黄皮叶多酚提取物的制备方法及其应用 Download PDFInfo
- Publication number
- CN107412393B CN107412393B CN201710333282.0A CN201710333282A CN107412393B CN 107412393 B CN107412393 B CN 107412393B CN 201710333282 A CN201710333282 A CN 201710333282A CN 107412393 B CN107412393 B CN 107412393B
- Authority
- CN
- China
- Prior art keywords
- extract
- polyphenol extract
- ethanol
- clausena lansium
- chinese wampee
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000089795 Clausena lansium Species 0.000 title claims abstract description 75
- 235000008738 Clausena lansium Nutrition 0.000 title claims abstract description 75
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 57
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 27
- 239000011347 resin Substances 0.000 claims abstract description 20
- 229920005989 resin Polymers 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 7
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003480 eluent Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 17
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 16
- 239000012535 impurity Substances 0.000 abstract description 7
- 150000002632 lipids Chemical class 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000003178 anti-diabetic effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 238000002137 ultrasound extraction Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 26
- 241000700159 Rattus Species 0.000 description 24
- 229930013930 alkaloid Natural products 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- -1 amide alkaloid Chemical class 0.000 description 7
- 229930003935 flavonoid Natural products 0.000 description 7
- 235000017173 flavonoids Nutrition 0.000 description 7
- 239000000341 volatile oil Chemical class 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000972673 Phellodendron amurense Species 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 206010006895 Cachexia Diseases 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000026500 emaciation Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005211 surface analysis Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- BAALMEGRQMMBJQ-UHFFFAOYSA-O 3-ethyl-12h-indolo[2,3-a]quinolizin-5-ium Chemical compound N1C2=CC=CC=C2C2=C1C1=CC=C(CC)C=[N+]1C=C2 BAALMEGRQMMBJQ-UHFFFAOYSA-O 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- BAALMEGRQMMBJQ-UHFFFAOYSA-N Flavopereirine Natural products N1=C2C=CC=CC2=C2C1=C1C=CC(CC)=CN1C=C2 BAALMEGRQMMBJQ-UHFFFAOYSA-N 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- 241000201320 Ligustrum japonicum Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000010718 Oxidation Activity Effects 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 240000005746 Ruta graveolens Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000592342 Tracheophyta Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000003889 chemical engineering Methods 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种黄皮叶多酚提取物的制备方法,其包括以下步骤:采用乙醇‑水为溶剂进行超声提取,将提取液浓缩后使用大孔树脂纯化,得到洗脱液,将洗脱液真空浓缩、干燥即得。采用该制备方法制得的黄皮叶多酚提取物含量为34.22~35.42%,不仅提取率高,且杂质少,用于制备食品或保健品或药品时可以减少用量,在一定程度上减少毒副作用,有利于产品的安全性和有效性。药理试验证明,本发明制得的黄皮叶多酚提取物具有明显的抗糖尿病效果,对糖尿病并发的血脂紊乱具有较佳的调节改善作用,可用于制备抗糖尿病、降血糖、降血脂的食品或保健品或药品。
Description
技术领域
本发明属于天然药物技术领域,具体涉及一种黄皮叶多酚提取物的制备方法及其应用。
背景技术
黄皮Clausena lansium(lour.)skeels是芸香黄皮属植物,广泛分布于东半球热带、亚热带地区,共有25个种,我国有10个种,分布于长江以南各省,大部分集中于云南、广东、广西、海南及台湾等省区。黄皮在广东、广西常栽培,资源丰富。其叶性味属辛,苦,平,《本草求原》中记载黄皮叶有“解秽除垢,退黄肿”之功用。在民间百姓常用其叶煮水洗浴用于治疗疥癞,消风肿等。其花小,果为浆果,果肉味甜或偏酸,含多种化合物,本属植物主要含有咔唑类生物碱、酰胺类生物碱、单萜基香豆素、多酚类化合物以及挥发油类化合物,具有清除自由基、抗氧化活性、保肝解毒、促智、解疫挛、抗细胞凋亡、降血糖血脂、抑菌、抗肿瘤及抗HIV病毒等生物活性。
植物多酚是一类广泛存在于植物体内的多元酚化合物,在维管植物中的含量仅次于纤维素、半纤维素和木质素,广泛存在于植物的叶、果、皮、根中,具有潜在促进健康的作用。已有研究证明,黄皮叶中的多酚化合物包含有槲皮素、山奈酚、芦丁、没食子酸、绿原酸、咖啡酸等,这些都具有很好的抗氧化、降血糖、降血脂的作用,具有潜在的医药保健价值。已公开的从黄皮叶中提取有效成分的工艺主要侧重于对生物碱、挥发油和黄酮类的提取,如李玉珍等在“响应面分析法优化黄皮叶中生物碱的提取工艺研究,广州化工”对从黄皮叶中提取生物碱的工艺条件进行优化,具体为在超声波辅助条件下,采用响应面分析法,以超声时间(A)、料液比(B)、溶媒浓度(C)等为主要影响因素,确定了生物碱最佳取工艺条件:在超声时间为49min,料液比为1:14,溶媒浓度为5.67%的条件下,黄皮叶中生物总碱的提取率为0.3560%。另有公开号为:CN104027436A的中国专利申请“一种黄皮叶提取物的制备方法”,以低碳醇为提取剂,进行超声波提取制备黄皮叶提取物,制得的提取物中生物碱的含量为55%以上。又有公开号为:CN106038766A的中国专利申请“一种小黄皮叶挥发油的提取方法及其应用”,以循环萃取方式对黄皮叶进行挥发油萃取,再通过分离釜减压解析,制得的小黄皮叶挥发油外观色泽好,该方法具有萃取效率高、提取量高、环保无污染等优点。
而现有技术对于从黄皮叶中提取多酚物质的研究相对较少,主要侧重于多酚类化合物之一的黄酮类化合物的提取,如梁云贞等在“微波辅助提取山黄皮叶黄酮类物质的工艺研究,广东农业科学”中披露采用热乙醇浸提、微波处理的步骤对山黄皮叶进行黄酮类化合物提取,提取率为3.90%,优于常规提取法。
综上所述,目前对黄皮叶提取已做的研究主要涉及生物碱、挥发油和黄酮类等,而在多酚物质的提取纯化及其应用的研究鲜为少见。因此,从黄皮叶中提取制备具有降糖降脂作用的多酚提取物,不仅能为更加有效、科学地开发和利用黄皮叶提供新思路与方向,而且也为抗糖尿病药物或保健品的研究开发提供实验基础。
发明内容
为解决现有技术存在的问题,本发明的目的在于提供一种黄皮叶多酚提取物的制备方法及其应用。
为实现上述目的,本发明采用的技术方案是:一种黄皮叶多酚提取物的制备方法,其包括以下步骤:
(1)将黄皮叶洗净,在50~60℃低温烘干,粉碎,过40-50目筛,得到黄皮叶粉末;
(2)以乙醇-水为溶剂,将黄皮叶粉末在超声波内,超声提取一次;
(3)将步骤(2)中所得的提取液真空浓缩至原体积的1/4~1/5,3000r/min离心10~15 分钟,除去不溶物,得到黄皮叶多酚提取物浓缩液;
(4)将上述浓缩液上已处理的大孔树脂,进行吸附、洗脱,收集洗脱液;
(5)将上述洗脱液真空浓缩,然后进行真空干燥,即得到黄皮叶多酚提取物。
其中,所述步骤(2)中的乙醇-水是体积分数为20~50%的乙醇,优选为25~35%的乙醇;所述黄皮叶粉末与提取溶剂的比例为1:40~1:50(g/mL);所述的超声条件为:超声功率为270~300W、提取温度为50~60℃、超声时间为50~60min。
进一步地,本发明采用的大孔树脂为苯乙烯型非极性或弱极性共聚体,优选为AB-8或 D-101,可有效提高黄皮总多酚的含量,大幅降低香豆素等杂质的含量。
具体地,上述对大孔树脂进行预处理的方法为:将大孔吸附树脂用95%乙醇浸泡24h,使树脂充分溶胀,再用95%乙醇清洗树脂至流出液体不呈白色浑浊,然后用去离子水洗至无醇味,备用。
进一步地,采用大孔树脂对浓缩液进行吸附、洗脱条件为:大孔树脂与生药量的质量比为:1:2~1:5,吸附时间为6~8小时,洗脱液依次为去离子水,10~40%乙醇溶液,洗脱速度为2~3mL/min,收集10~40%乙醇溶液的洗脱液,优选地,洗脱液依次为去离子水,30~40%乙醇溶液,洗脱速度为2~3mL/min,收集30~40%乙醇溶液的洗脱液。
具体地,上述对洗脱液进行真空浓缩的条件为:温度为50~60℃,真空度为0.05~0.1MPa,浓缩至原体积的1/5~1/6。
优选地,真空浓缩的温度为55~60℃,真空度为0.08~0.1MPa。
此外,本发明还请求保护根据上述的制备方法制得的黄皮叶多酚提取物以及所述的黄皮叶多酚提取物在制备抗糖尿病、降血糖、降血脂的食品或保健品或药品中的应用。
进一步地,在获得黄皮叶多酚提取物后,可用常规方法将其与药学上、食品学上或保健品上可接受的载体、赋形剂或稀释剂相混合,制成相应的制剂。这类载体包括(但并不限于):盐水、缓冲液、葡萄糖、水、甘油、乙醇、及其组合。
采用本发明提供的制备方法对黄皮叶进行多酚物质提取,得到黄皮叶多酚提取物含量为 34.22~35.42%,不仅提取率高,且杂质少,用于制备食品或保健品或药品时可以减少用量,在一定程度上减少毒副作用,有利于产品的安全性和有效性。药理试验表明,本发明制得的黄皮叶多酚提取物对链脲佐菌素(STZ)诱导的二型糖尿病大鼠的消瘦、多食、多饮和多尿的病理体征起到一定的控制和改善作用,对降低空腹血糖同样具有一定的作用。并且呈剂量依赖性地降低二型糖尿病大鼠的TC、TG和LDL-C值、升高HDL-C值,对血脂紊乱具有调节改善作用。
与现有技术相比,本发明的优势在于:
本发明以黄皮叶为原料,采用超声波有机溶剂法提取黄皮叶多酚成分,并用大孔树脂进行纯化,制备得到的黄皮叶提取物中多酚含量高,杂质少。药理试验证明,本发明制得的黄皮叶多酚提取物具有明显的抗糖尿病效果,对糖尿病并发的血脂紊乱具有较佳的调节改善作用。此外,本发明的制备方法简单、周期短,为黄皮叶的药用开发和黄皮叶的综合利用作出巨大贡献。
具体实施方式
以下通过具体实施方式进一步描述本发明,但本发明不仅仅限于以下实施例。
实施例1 黄皮叶多酚提取物的制备
称取100g黄皮叶在60℃下低温烘干,粉碎,过40目筛,得到黄皮叶粉末;在乙醇浓度为30%、提取超声功率为280W、提取温度为50℃、提取时间50min、料液比1:40(g/mL) 条件下提取,得到黄皮叶多酚提取液;将提取液真空浓缩至原体积的1/5,经3000r/min离心15分钟去除不溶于水的杂质,得到黄皮叶多酚提取物浓缩液;将浓缩液上已处理的大孔树脂AB-8进行吸附、洗脱,吸附时间为8小时,洗脱液依次为去离子水,30%乙醇溶液,洗脱速度为2mL/min,各洗至近无色,收集30%乙醇溶液的洗脱液,真空浓缩,55℃真空干燥,即得到黄皮叶多酚提取物,其含量为35.42%。
实施例2 黄皮叶多酚提取物的制备
称取100g黄皮叶在55℃下低温烘干,粉碎,过筛,得到黄皮叶粉末;在乙醇浓度为30%、提取超声功率为280W、提取温度为60℃、提取时间55min、料液比1:45(g/mL)条件下提取,得到黄皮叶多酚提取液;将提取液真空浓缩至原体积的1/5,经3000r/min离心15分钟去除不溶于水的杂质,得到黄皮叶多酚提取物浓缩液;将浓缩液上已处理的大孔树脂AB-8 进行吸附、洗脱,吸附时间为6小时,洗脱液依次为去离子水,30%乙醇溶液,洗脱速度为 2mL/min,各洗至近无色,收集30%乙醇溶液的洗脱液,真空浓缩,60℃真空干燥,即得到黄皮叶多酚提取物,其含量为34.42%。
实施例3 黄皮叶多酚提取物的制备
称取100g黄皮叶在60℃下低温烘干,粉碎,过筛,得到黄皮叶粉末;在乙醇浓度为30%、提取超声功率为280W、提取温度为60℃、提取时间55min、料液比1:45(g/mL)条件下提取,得到黄皮叶多酚提取液;将提取液真空浓缩至原体积的1/4,经3000r/min离心15分钟去除不溶于水的杂质,得到黄皮叶多酚提取物浓缩液;将浓缩液上已处理的大孔树脂D-101进行吸附、洗脱,吸附时间为6小时,洗脱液依次为去离子水,30%乙醇溶液,洗脱速度为3mL/min,各洗至近无色,收集30%乙醇溶液的洗脱液,真空浓缩,60℃真空干燥,即得到黄皮叶多酚提取物,其含量为34.22%。
试验例一、黄皮叶多酚提取物抗糖尿病、降血糖、降血脂的作用研究
(1)黄皮叶多酚提取物对链脲佐菌素(STZ)诱导的二型糖尿病大鼠血糖及生理特征的影响
选取体重为180~220g的Wistar雄性健康大鼠40只,随机选取5只为正常对照组,喂食普通饲料,其余的大鼠用高脂饲料喂养两周后,腹腔注射STZ 60mg/kg复制大鼠糖尿病模型。从模型大鼠中剔除个别空腹血糖值异常者,挑选出合格糖尿病大鼠20只,分为4组,每组5只,分被为:二甲双胍阳性对照组(100mg/kg)、模型对照组、黄皮叶多酚提取物高、低剂量组(100mg/kg,50mg/kg),然后灌胃给药,每天1次,连续4周。正常组和模型对照组大鼠给予等量生理盐水。各组大鼠给药前称体重,给药后每天观察记录其精神活动、毛发改变、饮水量、进食量、大小便等一般生活状况,每周称量一次大鼠体重,比较给药前后体重变化情况,以实验前后4项指标表明药物对各组大鼠生长情况的影响,结果见表1-5。
表1 黄皮叶多酚提取物对二型糖尿病大鼠体重变化的影响
注:与模型对照组相比,*P<0.05;与正常组相比,#P<0.05。
表2 黄皮叶多酚提取物对二型糖尿病大鼠***量变化的影响
注:与模型对照组相比,*P<0.05;与正常组相比,#P<0.05。
表3 黄皮叶多酚提取物对二型糖尿病大鼠饮水量变化的影响
注:与模型对照组相比,*P<0.05;与正常组相比,#P<0.05。
表4 黄皮叶多酚提取物对二型糖尿病大鼠进食量变化的影响
注:与模型对照组相比,*P<0.05;与正常组相比,#P<0.05。
表5 黄皮叶多酚提取物对二型糖尿病大鼠空腹血糖变化的影响
由上表1-5可知,经过四周给药后,与模型对照组比较,黄皮叶多酚提取物高、低剂量组糖尿病大鼠生活状况有所改善,体重增加,进食量、饮水量、***量减少,空腹血糖值降低。结果表明,黄皮叶多酚提取物对对链脲佐菌素诱导的二型糖尿病大鼠的消瘦、多食、多饮和多尿的病理体征起到一定的控制和改善作用,且对降低空腹血糖具有一定的作用。
(2)黄皮叶多酚提取物对链脲佐菌素诱导的二型糖尿病大鼠血脂的调节作用影响
大鼠模型的建立、给药的方式、剂量及时间均同上(1)所述,在给药前和给药4周后取血按试剂盒所述方法测总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C) 和高密度脂蛋白胆固醇(HDL-L)值,结果见表6。
表6 黄皮叶多酚提取物对二型糖尿病大鼠血脂的作用
注:与模型对照组相比,*P<0.05;**P<0.01。
由上表6可知,在给药前,各模型组的血脂值无明显区别;给药四周后,与模型对照组比较,低剂量、高剂量和阳性对照组的TC、TG和LDL-C值均有所降低,且具有显著性意义(P<0.05或P<0.01),其中高剂量组较低剂量组的结果好,与阳性对照组的值接近;与模型对照组相比,低剂量、高剂量和阳性对照组的HDL-C值明显上升,具有显著性意义 (P<0.01)。结果表明,黄皮叶多酚提取物对二型糖尿病大鼠的血脂紊乱具有调节改善作用,且呈剂量依赖性。
以上仅是本发明的优选实施方式,应当指出的是,上述优选实施方式不应视为对本发明的限制,本发明的保护范围应当以权利要求所限定的范围为准。对于本技术领域的普通技术人员来说,在不脱离本发明的精神和范围内,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (5)
1.一种黄皮叶多酚提取物的制备方法,其特征在于,包括以下步骤:
(1)将黄皮叶洗净,在50℃低温烘干,粉碎,过40目筛,得到黄皮叶粉末;
(2)以乙醇-水为溶剂,将黄皮叶粉末在超声波内,超声提取一次;
(3)将步骤(2)中所得的提取液真空浓缩至原体积的1/5,3000r/min离心15分钟,除去不溶物,得到黄皮叶多酚提取物浓缩液;
(4)将上述浓缩液上已处理的大孔树脂,进行吸附、洗脱,收集洗脱液;
(5)将上述洗脱液真空浓缩,然后进行真空干燥,即得到黄皮叶多酚提取物;
所述步骤(2)中的乙醇-水是体积分数为30%的乙醇;
所述步骤(2)中黄皮叶粉末与提取溶剂的比例为1:40(g/mL);
所述步骤(2)中的超声条件为:超声功率为280W、提取温度为50℃、超声时间为50min;
所述步骤(4)中的大孔树脂为AB-8。
2.根据权利要求1所述的黄皮叶多酚提取物的制备方法,其特征在于,所述步骤(4)中的大孔树脂处理方法为:将大孔吸附树脂用95%乙醇浸泡24h,使树脂充分溶胀,再用95%乙醇清洗树脂至流出液体不呈白色浑浊,然后用去离子水洗至无醇味,备用。
3.根据权利要求1所述的黄皮叶多酚提取物的制备方法,其特征在于,所述步骤(4)中的吸附、洗脱条件为:大孔树脂与生药量的质量比为:1:2~1:5,吸附时间为8小时,洗脱液依次为去离子水,30%乙醇溶液,洗脱速度为2mL/min,收集30%乙醇溶液的洗脱液。
4.根据权利要求1所述的黄皮叶多酚提取物的制备方法,其特征在于,所述步骤(5)中的真空浓缩的条件为:温度为55℃,真空度为0.05~0.1MPa,浓缩至原体积的1/5。
5.根据权利要求1-4任一所述的制备方法制得的黄皮叶多酚提取物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710333282.0A CN107412393B (zh) | 2017-05-12 | 2017-05-12 | 一种黄皮叶多酚提取物的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710333282.0A CN107412393B (zh) | 2017-05-12 | 2017-05-12 | 一种黄皮叶多酚提取物的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107412393A CN107412393A (zh) | 2017-12-01 |
CN107412393B true CN107412393B (zh) | 2020-09-29 |
Family
ID=60425062
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710333282.0A Active CN107412393B (zh) | 2017-05-12 | 2017-05-12 | 一种黄皮叶多酚提取物的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107412393B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114113374A (zh) * | 2021-11-09 | 2022-03-01 | 广东济公保健食品有限公司 | 一种黄皮中物质成分的提取方法以及资源回收方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106491503A (zh) * | 2016-12-14 | 2017-03-15 | 黄文庆 | 黄皮叶有效成分的提取方法及其制备护肤霜的用途 |
CN106521993A (zh) * | 2016-11-02 | 2017-03-22 | 常州创索新材料科技有限公司 | 一种环保型高温匀染剂的制备方法 |
-
2017
- 2017-05-12 CN CN201710333282.0A patent/CN107412393B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106521993A (zh) * | 2016-11-02 | 2017-03-22 | 常州创索新材料科技有限公司 | 一种环保型高温匀染剂的制备方法 |
CN106491503A (zh) * | 2016-12-14 | 2017-03-15 | 黄文庆 | 黄皮叶有效成分的提取方法及其制备护肤霜的用途 |
Non-Patent Citations (3)
Title |
---|
HPLC法测定黄皮叶醇提取物中芦丁的含量;丁莹等;《亚太传统医药》;20160531;第12卷(第9期);第33-34页 * |
黄皮叶不同溶剂提取物抗过敏活性研究;赵丰丽等;《食品工业科技》;20091231(第1期);第110-112、115页,尤其是第111页左栏"11211"第1-2段、倒数第1-2段,右栏第1段,表1, * |
黄皮叶对链脲佐菌素诱导的糖尿病大鼠的作用及机制研究;黄小桃等;《中药新药与临床药理》;20141130;第25卷(第6期);第651-656页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107412393A (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1271083C (zh) | 从竹子中提取的三萜总皂甙元的组成、方法及其用途 | |
CN102526315B (zh) | 一种荔枝核有效部位群提取物的制备方法 | |
CN101463061A (zh) | 三七中人参皂苷Rg1、Rb1及其总皂苷的制备方法 | |
CN1349820A (zh) | 文冠果果壳提取物在制备提高脑功能食品和药品中的应用 | |
CN112870236B (zh) | 一种黄蜀葵花黄酮类有效部位及其制备方法与应用 | |
CN109303794B (zh) | 一种富硒堇叶碎米荠提取物及其在肝脏保护方面的应用 | |
KR20190075266A (ko) | 진세노사이드 F2, Rg3 및 컴파운드 케이 고함량 숙취 예방 및 해소용 액상조성물 및 그 제조방법 | |
CN109601795A (zh) | 以赶黄草为主要原料的组合物解酒饮料及其制备方法 | |
CN107412393B (zh) | 一种黄皮叶多酚提取物的制备方法及其应用 | |
CN102988457A (zh) | 一种灰毡毛忍冬叶的总黄酮提取物、制备方法及其应用 | |
CN104306732A (zh) | 一种金斛软胶囊及其制备方法 | |
CN106473995A (zh) | 鬼针草有效成分的提取方法及其制备面膜的用途 | |
CN109223865B (zh) | 一种桑叶生物碱的制备方法及制备得到的桑叶生物碱的应用 | |
CN104758309B (zh) | 树莓多糖降血糖的用途 | |
KR0180567B1 (ko) | 복방 생약제로부터 유효활성 성분의 추출.정제방법과 그 추출물을 함유한 생약 조성물 | |
CN105963355A (zh) | 一种防治老年痴呆症的药物 | |
TWI438001B (zh) | 用於治療糖尿病之植物萃取物及其製備方法 | |
CN101278974A (zh) | 一种肉桂皂甙提取物及其制备方法和应用 | |
CN1687092A (zh) | 苍耳子总苷提取物及其制备方法 | |
CN112168848A (zh) | 一种海蓬子降血糖组分的制备方法及应用 | |
CN100488543C (zh) | 大蒜局部外用止痒涂剂 | |
CN111888431A (zh) | 一种治疗糖尿病的组合物及其制备方法 | |
CN104958582A (zh) | 一种淡竹叶提取物、含其制剂及用途 | |
CN110679688A (zh) | 一种蜂蜜乌龙茶饮品 | |
CN1597690A (zh) | 红景天苷类化合物的富集方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |